HomeHomeJournal CollectionJournal SocietiesMeeting Calendar
Logo
Search for

Volume 81, Issue 2, Pages 136-142 (November 2006)


View previous. 6 of 20 View next.

A prospective phase II study of adjuvant postoperative radiation therapy following nodal surgery in malignant melanoma–Trans Tasman Radiation Oncology Group (TROG) Study 96.06

Bryan H. BurmeisteraCorresponding Author Informationemail address, B. Mark Smithersa, Elizabeth Burmeisterb, Kathryn Baumannc, Sidney Davisd, Hedley Krawitze, Carol Johnsonf, Nigel Spryg

Received 24 May 2006; received in revised form 25 September 2006; accepted 2 October 2006. published online 25 October 2006.

Abstract 

Background

The role of adjuvant postoperative therapy after resection of localised malignant melanoma involving regional lymph nodes remains controversial. There are no randomised trials that confirm that postoperative radiation conveys a benefit in terms of regional control or survival.

Methods

Two hundred and thirty-four patients with melanoma involving lymph nodes were registered on a prospective study to evaluate the effect of postoperative radiation therapy. The regimen consisted of 48Gy in 20 fractions to the nodal basin using recommended treatment guidelines for each of the major node sites. The primary endpoints were regional in-field relapse and late toxicity. Secondary endpoints were adjacent relapse, distant relapse, overall survival, progression-free survival and time to in-field progression.

Results

Adjuvant radiation therapy was well tolerated by all of the patients. As the first site of relapse, regional in-field relapses occurred in 16/234 patients (6.8%). The overall survival was 36% at 5 years. The progression-free survival and regional control rates were 27% and 91%, respectively, at 5 years. Patients with more than 2 nodes involved had a significantly worse outcome in terms of distant relapse, overall and progression-free survival.

Conclusion

We believe that adjuvant radiation therapy following nodal surgery could offer a possible benefit in terms of regional control. These results require confirmation in a randomised trial.

a University of Queensland, Melanoma Clinic, Princess Alexandra Hospital, Brisbane, Australia

b Queensland Cancer Control Analysis Team, Brisbane, Australia

c Radiation Oncology Mater Centre, Brisbane, Australia

d William Buckland Radiotherapy Centre, Melbourne, Australia

e Auckland Hospital, Auckland, New Zealand

f Wellington Hospital, Wellington, New Zealand

g Sir Charles Gairdner Hospital, Perth, Australia

Corresponding Author InformationCorresponding author. Bryan H. Burmeister, University of Queensland, Princess Alexandra Hospital, Woolloongabba 4102, Australia.

 The study was conducted as a multi-centre trial under the auspices of the Trans Tasman Radiation Oncology Group (TROG).

PII: S0167-8140(06)00529-9

doi:10.1016/j.radonc.2006.10.001


View previous. 6 of 20 View next.